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Familial aggregation is a significant risk factor for the development of thyroid cancer and familial non-medullary thyroid cancer
(FNMTC) accounts for 5–7% of all NMTC. Whole exome sequencing analysis in the family affected by FNMTC with oncocytic
features where our group previously identified a predisposing locus on chromosome 19p13.2, revealed a novel heterozygous
mutation (c.400G>A, NM_012335; p.Gly134Ser) in exon 5 of MYO1F, mapping to the linkage locus. In the thyroid FRTL-5 cell
model stably expressing the mutant MYO1F p.Gly134Ser protein, we observed an altered mitochondrial network, with
increased mitochondrial mass and a significant increase in both intracellular and extracellular reactive oxygen species, com-
pared to cells expressing the wild-type (wt) protein or carrying the empty vector. The mutation conferred a significant advan-
tage in colony formation, invasion and anchorage-independent growth. These data were corroborated by in vivo studies in
zebrafish, since we demonstrated that the mutant MYO1F p.Gly134Ser, when overexpressed, can induce proliferation in whole
vertebrate embryos, compared to the wt one. MYO1F screening in additional 192 FNMTC families identified another variant in
exon 7, which leads to exon skipping, and is predicted to alter the ATP-binding domain in MYO1F. Our study identified for the
first time a role for MYO1F in NMTC.
Introduction
Familial aggregation is a signiﬁcant risk factor for the devel-
opment of thyroid cancer derived from follicular epithelial
cells (non-medullary thyroid carcinoma, NMTC). When the
primary cancer site is considered, the thyroid gland shows
the highest estimate of familial relative risk among all organs
(5- to 10-fold compared to 1.8 and 2.7 for breast and colon
cancer, respectively).1 Familial NMTC (FNMTC) accounts
for 5–7% of all NMTC and may occur as a part of familial
cancer syndromes (familial adenomatous polyposis, Gardner’s
syndrome, Cowden’s disease, Carney’s complex type 1, Wern-
er’s syndrome and papillary renal neoplasia) or as a primary
feature (familial NMTC) (for a review see Ref. 2,3). FNMTC
has become a well-recognized, unique clinical entity.
Although still debated, there are some epidemiologic and
clinical kindred studies that have shown an association
between FNMTC and more aggressive behavior than sporadic
cases, with higher rates of multicentric tumors, lymph node
metastasis and extrathyroidal invasion, a younger age of
onset and shorter disease-free survival.2–4 A search for
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susceptibility genes, undertaken using linkage-based app-
roaches, led to the identiﬁcation of several predisposing loci:
MNG1 (14q32), TCO (19p13.2), fPTC/PRN (1q21), NMTC1
(2q21), FTEN (8p23.1-p22) and the telomere–telomerase
complex.2,3 Mutations were identiﬁed at the 14q31 locus in the
DICER1 gene, which encodes for an enzyme required for
miRNA maturation.5 Recent data have also shown that dysregu-
lation of miRNA expression is a hallmark of thyroid cancer6
and an altered splicing regulation has been reported in FNMTC
patients carrying a germline mutation in the SRRM2 gene,
encoding a splicing machinery subunit.7 Additional studies have
identiﬁed predisposing risk-variants in non-coding genes,
including miRNAs8 and a long non-coding gene PTCSC2.9
Mutations in genes encoding regulators of the RAS pathway
such as RASAL110 and SRGAP111 were also identiﬁed in
FNMTC cases. Taken together, these data indicate that the
genetic predisposition to FNMTC is characterized by a high
degree of heterogeneity, hampering the identiﬁcation of the
underlying mutations in the corresponding pedigrees.
We previously mapped a predisposing locus for FNMTC
on chromosome 19p13.2 in a multigenerational family with
multiple individuals affected by thyroid carcinoma with
oncocytic features (oxyphilia; TCO), with autosomal domi-
nant inheritance.12 In our study, we report whole exome
sequencing (WES) data and functional studies providing evi-
dence that mutant MYO1F, mapping to the TCO locus on
chromosome 19p13.2, lead to NMTC.
Materials and Methods
The study was approved by the committee for protection of
persons in biomedical research of Lyon (CCPRB A-96.18)
and by the IARC Ethical Review Board (Project 95–050,
amendment 01–013). Informed consents were obtained by
clinicians, in each collaborating center.
Subjects
The TCO family has been previously reported12 and the
main clinical characteristics are reported in the Supporting
Information. Papillary thyroid carcinomas (PTCs) were diag-
nosed in individuals II-5, III-3 and III-7 at the ages of 41, 27
and 11 years, respectively. In total, 192 FNMTC patients
included in the mutation screening came from the families
collected between 1996 and 2012 through the International
Consortium for the Genetics of Non-Medullary Thyroid
Carcinoma; 149 female patients and 43 males were included
(age of onset: 11–84 years, mean age5 42 years), thyroid
cancer diagnosis is reported in Supporting Information Table
S1.
WES analysis
WES was performed on three individuals from the TCO fam-
ily, two affected by thyroid carcinoma with oncocytic features
(individuals II-3; III-7, Fig. 1a) and one affected by adenoma
(II-4), according to the pipeline reported in the Supporting
Information. Variants were conﬁrmed by polymerase chain
reaction (PCR) and direct sequencing.
Cell lines
The FRTL-5 cell line is a stable thyroid cell line derived from
normal thyroid glands from 5 to 6-week-old Fisher rats.13 All
cells were cultured in 6H5 medium consisting of Coon’s
modiﬁed Ham’s F12 medium (Sigma-Aldrich, St. Louis, MO)
supplemented with 5% newborn calf serum (NCS) (Sigma-
Aldrich), 1 lg/ml insulin, 10 nM hydrocortisone, 5 lg/ml
apo-transferrin, 10 ng/ml gly-his-lys, 10 ng/ml somatostatin,
1 mU/ml TSH (Sigma-Aldrich, St. Louis, MO) and penicillin/
streptomycin (EuroClone, Milan, Italy). Cells were propa-
gated in a fully humidiﬁed atmosphere of 5% CO2 at 378C.
COS7 cells derived from monkey kidney tissue were grown
in Dulbecco’s modiﬁed Eagle’s medium, 10% fetal bovine serum,
2 mM L-glutamine, 100 U/ ml penicillin and 100 lg/ml strepto-
mycin, in a humidiﬁed incubator at 378C with 5% CO2.
pCMV6-MYO1F p.Gly134Ser plasmid generation via site-
directed mutagenesis
The construct pCMV6 encoding wild-type (wt) MYO1F
(RC207069) was purchased from OriGene OriGene Technol-
ogies, Rockville, MD) in frame with the tag (polypeptide
chain containing the aminoacid sequence Asp-Tyr-Lys-Asp-
Asp-Asp-Asp-Lys, or DYKDDDDK (DDK) and containing
neomycin resistance (G418) for stable selection. The muta-
tion c.400G>A was inserted using the Q5 Site-direct Muta-
genesis kit, according to the manufacturer’s instruction (New
England Biolabs, Ipswich, MA) using the oligonucleotides for-
ward 50-AGGTGTCTGGCGGAAGCGAGAAGGTCCAG-30 and
reverse 50-TGGAGATGTAGCCCATGATTATTTGGCT-30.
The site-directed mutagenesis was veriﬁed by plasmid direct
sequencing.
What’s new?
Evidence suggests that familial non-medullary thyroid carcinoma (FNMTC) is highly heterogeneous, complicating the identifica-
tion of underlying mutations in family pedigrees. Here, investigation of chromosome 19p13.2, which contains a known thyroid
cancer-predisposing locus, led to the identification of a novel mutation in the gene MYO1F. Relative to wild-type controls, thy-
roid cell models carrying mutant MYO1F exhibited a significant increase in colony formation and greater potential for invasion
and anchorage-independent growth. Mutated cells further showed an altered mitochondrial phenotype, similar to the one
observed in human thyroid tumors. The findings suggest that MYO1F has a role in thyroid cancer predisposition.
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Figure 1. Study of MYO1F p.Gly134Ser variant. (a) Pedigree of the TCO family: electropherograms of the sequences of available family mem-
bers, showing the co-segregation of the change (in red) with the oncocytic carcinoma (black)/adenoma (grey) phenotype. (b–h) Functional
analysis of the MYO1F p.Gly134Ser variant. All experiments were repeated at least three times. Scale bars indicate standard error, stars
indicate p<0.05. (b) Western blot analysis showing the recombinant MYO1F protein in stably expressing FRTL-5 cells, using a specific anti-
DDK antibody. Cell stably transfected with the empty vector are indicated as pCMV6-empty. Cells stably expressing the wt protein are indi-
cated as pCMV6-MYOF wt, cells stably expressing the mutant protein are indicated as pCMV6-MYOF G134S. (c) SRB assay showed a signifi-
cant increase in cell growth and proliferation for the pCMV6-MYOF G134S cells. (d) Plate colony formation potential using SRB assay
showing an increased number of colonies formed by FRTL-5 expressing the mutant MYO1F protein, compared to cells expressing either the
empty vector or the wt protein. (e) Growth in soft agar: FRTL-5 cells expressing the MYO1F mutant protein p.Gly134Ser significantly gener-
ated more colonies, compared to the empty and the cells expressing the wt protein. (f) Wound healing assay: FRTL-5 cells expressing the
MYO1F mutant protein p.Gly134Ser filled the gap significantly faster compare to the other two cell lines. (g, h) Western blotting analysis of
ERK1/2 phosphorylation in the three cell lines and densitometric quantification. [Color figure can be viewed at wileyonlinelibrary.com]
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Generation of FRTL-5-stably transfected cell lines
A 7.5-lg of pCMV6 empty, pCMV6-MYO1F-wt and
pCMV6-MYO1F-G134S plasmids were transfected using lipo-
somes according to the manufacturer’s instructions (Lipofect-
amine 2000, ThermoFisher Scientiﬁc, Grand Island, NY).
Forty eight hours after transfection, selection was obtained by
supplementing complete medium with 500 lg/ml G418
(ThermoFisher Scientiﬁc) for 2 weeks. Isolated clones were
grown with 200 lg/ml G418.
Western blot
A detailed protocol is reported in the Supporting Informa-
tion, including the list of primary antibodies used.
Sulforhodamine B (SRB) assay to investigate cell
proliferation and plate colony formation
For cell growth and proliferation assays, 2.5 3 105 cells were
seeded in duplicate and incubated 96 hours at 378C. For plate
colony formation, 2.5 3 104 cells were seeded in duplicate
and incubated for 20 days at 378C. Cells were washed in
phosphate-buffered saline (PBS) and ﬁxed with cold tri-
chloroacetic acid (TCA) 50% at 48C for 1 hr, then TCA was
eliminated and cells were dried at room temperature for 16
hrs. Cells were stained with SRB 0.4% in 1% acetic acid for
30 min, washed with 1% acetic acid for four times. For the
proliferation assay, cells were solubilized in TrisHCl 10 mM
pH 10.5, mixing for 10 min on a rotatory plate. Absorbance
was read at k5 564 nm using a Beckman Coulter DU-530
spectrophotometer. For plate colony assay, cells were photo-
graphed with ChemiDoc XRS1 (Biorad). Area and number
of colonies were quantiﬁed with the ImageJ software
(National Institute of Health, Bethesda, MD) discarding colo-
nies <1 pixel.
Soft agar colony assay
Stable cell lines were seeded in triplicate in a 0.48% top agar in
growth medium over a layer of 0.8% agar in a six-well plate at
a density of 1 3 105 cells/ml. Plates were incubated at 378C
and 5% CO2 for 12 days, monitoring for colony formation.
Medium was replaced every 5 days. After 12 days, colonies were
photographed and analyzed with ImageJ software.
Wound healing assay
Stable cell lines were plated onto six-well plates and allowed to
form a conﬂuent monolayer. The cell monolayer was then
scratched in a straight line to make a “scratch wound” with a
10-ll tip and the cell debris was removed by washing the cells
with PBS. 5H5 (6H5 medium without Thyroid-Stimulating Hor-
mone (TSH)) medium supplemented with 10% NCS and 200
lg/ml of neomycin was added with or without 1 mM N-acetyl-
L-cysteine (NAC), and images of the closure of the scratch were
captured at 0 and 7 days. Images were analyzed with the
TScratch software.14
Iodide transport
Iodide uptake by FRTL-5 cells was measured by live cell
imaging with the ﬂuorescent halide biosensor yellow ﬂuores-
cent protein (YFP)-H148Q/I15L, as described previously.15,16
Mitochondrial morphology and mass assessment via live
cell imaging
Mitochondrial morphology was assessed by live imaging with
or without 1 mM NAC, using a Nikon Eclipse 80 microscope
(Nikon, Tokio, Japan) according to Ref. 17. Circularity meas-
urements were collected using ImageJ standard tools.
Mitochondrial mass measurements
In 96-well culture plates, 1 3 104 FRTL-5-stable cell lines
were seeded in quadruplicates. The next day, cells were
loaded with 50 nM MitoTracker Green (MTG) for 30 min at
378C in complete medium. After washing twice with
medium, MTG ﬂuorescence was recorded in a plate reader
(EnSpire, PerkinElmer). MTG ﬂuorescence values were
expressed as relative ﬂuorescence unit (RFU)/viable cells. Cell
viability was assessed with a resazurin-based method.
Mitochondrial potential measurement via JC-1
The ﬂuorescent probe JC-1 (5, 50,6, 60-tetrachloro-1, 10, 3, 30-
tetraethylbenzimidazol carbocyanine iodide) was used to
measure the mitochondrial membrane potential (D/), as
described in the Supporting Information.
Cellular respiration
Oxygen consumption in intact cells. Approximately 1.5 3 106
FRL5-stable cell lines were harvested at 70–80% conﬂuence,
washed in PBS, resuspended in complete medium and assayed
for oxygen consumption at 308C using a thermostatically con-
trolled oxygraph chamber (Instech Mod. 203, Plymouth Meet-
ing, PA). Basal respiration was measured in their respective
media and compared with the one obtained after injection of
oligomycin (1 lM) and Carbonyl cyanide-p-triﬂuoromethoxy-
phenylhydrazone (FCCP) (1–6 lM). Antimycin A (5 mM) was
added at the end of experiments to completely block the mito-
chondrial respiration. Data were normalized to protein content
determined by the Lowry method.
ATP/ADP synthesis ratio determination. Nucleotides were
extracted and detected using a Kinetex C18 column (250 3
4.6 mm, 100 Å, 5 lm; Phenomenex, CA), with a two pump
Agilent 1100 series system. Absorbance (260 nm) was moni-
tored with a photodiode array detector (Agilent 1100 series
system). Nucleotide peaks were identiﬁed by comparison and
coelution with standards and quantiﬁcation by peak area
measurement compared with standard curves.18
ROS quantification
Intracellular ROS. FRTL-5-stable cell lines were seeded at
5 3 104 cells per well and incubated 16 hrs. Cells were
treated with 10 mM 2’,7’-dichlorodihydroﬂuorescein diacetate
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(DCFDA) dissolved in medium for 1 hr. Then, cells were
washed twice with PBS and incubated for 12 hrs in complete
medium. Finally, cells were washed with PBS and the ﬂuores-
cence emission from each well was measured
(kexc5 485 nm; kem5 535 nm) with a multi-plate reader
(Enspire, Perkin Elmer). Data are reported as the mean6 SD
of at least three independent experiments.
Extracellular ROS. FRTL-5-stable cell lines were seeded at
5 3 104 cells per well and incubated 16 hrs. Cells were
treated with 10 mM Amplex red (N-acetyl-3,7-dihydroxyphe-
noxazine), 0.025 U/ml horseradish peroxidase dissolved in
complete medium for 16 hrs. The medium was collected and
measured (kexc 530, kem 590) with a multiplate reader (Ens-
pire, Perkin Elmer). Data were normalized for cell number
using resazuring assay. Data are reported as the mean6 SD
of at least three independent experiments.
In vivo study of mutant MYO1F
Zebraﬁsh embryos and adults were maintained and mated
according to standard procedures. Mutant and wt capped
MYO1F mRNAs were synthesized with the SP6 mMESSAGE
mMACHINE kit (Ambion, ThermoFisher Scientiﬁc) using as
template the PCS21MYO1F-G134S and PCS21MYO1F-wt
plasmids, respectively. wt zebraﬁsh embryos were injected at
one-cell stage with 150 pg of MYO1F-wt or MYO1F-G134S
mRNA and then ﬁxed at 48 hrs post fertilizations (hpf). To
determine the cell proliferation patterns, a whole-mount
immunostaining with the anti-phospho-Histone H3 (pH3)
antibody (Millipore, Darmstadt, Germany) was performed.
We counted the mitotic cells along the trunk of each ﬁsh
(from the yolk extension to the tip of the tail) and calculated
the average number of pH3-positive cells per embryo to com-
pare the difference among groups. Statistical analysis was
performed using Student’s unpaired t test. Differences were
considered signiﬁcant for p< 0.05.
MYO1F mutation screening in FNMTC pedigrees
PCR primers for human MYO1F (NM_012335) were designed
with Primer3 v4.0 (http://primer3.ut.ee) and are available on
request. Genomic DNA extracted from peripheral blood was
ampliﬁed according to standard PCR conditions, and PCR
products were analyzed by direct sequencing, as reported in the
Supporting Information.
P1 pAltermax MYO1F exon 7-minigene generation
PCR of MYO1F genomic region encompassing exons 7 and
8 was performed using primer forward 50 GGGGAATT-
CAGAAGGGAAGAGAGGCAAGG-30, inserting an EcoRI
restriction site, and primer reverse 50-CCCTCTAGAAAC-
TCAGGAGGGTTTCTGGG-30, inserting an XbaI restriction
site from a heterozygous carrier. We generated the mini-
gene reporter as described previously.19 The PCR products
were cloned into the digested P1 pAltermax and plasmids
sequenced to identify the plasmids with the wt or the
variant alleles. The splicing alteration analysis was per-
formed as reported in Ref. 19 and in Supporting
Information.
Structural modeling
Modeling of the protein structure was performed adopting a
building obtained by comparison procedures based on MOD-
ELLER (https://salilab.org/modeller/). The template was
MYO1C_HUMAN (PDB code: 4BYF_A), and the ﬁnal struc-
tural superimposition indicated a 45% sequence identity
among the computed and experimental structures. Given the
coverage of the template to the target, modeling was possible
in the protein region spanning amino acids 16–714. From
structural superimposition, it was also possible to locate the
ATP-binding domain.
Statistical analysis
Statistical analyses were performed using the one-way analy-
sis of variance (ANOVA) with Tukey’s multiple comparison
test. All tests were completed using Prism (GraphPad, San
Diego, CA). A p< 0.05 was considered statistically signiﬁcant.
All experiments were carried out at least in triplicates.
Results
Identification of a novel missense mutation in MYO1F
conferring tumor-like properties to thyroid cells
WES was performed in three members of the original TCO
family where the linkage locus was identiﬁed12 (II-3, II-4 and
III-7; Fig. 1a), in two individuals affected by thyroid carci-
noma and one affected by thyroid adenoma, all with onco-
cytic features. All variants were queried with ANNOVAR
and ﬁltered based on Single Nucleotide Polymorphisms Data-
base (dbSNP) database annotation. Potentially deleterious
mutations were selected according to their functional class,
and prioritization was given to those lying in the chr19p13.2
linkage region and present in all three cases. A unique novel
heterozygous variant in the linkage interval shared by all
three individuals fulﬁlled the criteria for pathogenicity: the
mutation c.400G>A in MYO1F cDNA (NM_012335), lead-
ing to a missense p.Gly134Ser substitution, predicted to be
damaging by PolyPhen-2 and Provean (Supporting Informa-
tion Table S2), not present in the NHLBI Exome Sequencing
Project (ESP), in the Exome Aggregation (ExAc) and
Genome Aggregation (gnomAD) databases and absent from
1000 in-house control chromosomes. The variant co-
segregated with the carcinoma/adenoma phenotype in the
family and appeared to be a likely candidate for the NMTC
gene residing at 19p13.2 (Fig. 1a). MYO1F consists of 28
exons encoding a 1098-amino-acid protein of the class of
unconventional myosins.20 The p.Gly134Ser amino acid
change resides in a very well conserved position in the ATP-
binding domain of the protein. Since thyroid tumor tissue
from patients was not available for additional studies, we
generated cell models stably expressing the wt or mutant
MYO1F (mut) after transfection with the corresponding
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episomal plasmids, and a control cell line stably expressing
the corresponding empty vector, pCMV6, via G418 selection.
We used highly differentiated and functional FRTL-5 rat thy-
roid cell line13 to reveal the effects of the MYO1F variant.
The p.Gly134Ser mutation was inserted by site-directed
mutagenesis in the construct encoding wt MYO1F in frame
with the DDK tag. Western blotting with anti-DDK antibody
in stably transfected cells showed that both wt and mut pro-
teins were expressed in similar amounts (Fig. 1b). Stable cell
lines expressing either the wt or the mut MYO1F protein
were tested for their proliferative and tumorigenic potential
in comparison with cells transfected with the empty vector.
A signiﬁcant increase in the proliferation was observed in
mut cells, compared to cells expressing either the empty vec-
tor or the wt recombinant protein (one-way ANOVA with
Tukey’s multiple comparisons test p5 0.0044; pCMV6 empty
vs. pCMV6-MYO1F G134S, p5 0.0092; pCMV6-MYO1F WT
vs. pCMV6-MYO1F G134S p5 0.0072; pCMV6 empty vs.
pCMV6-MYO1F WT p5 0.9853, Fig. 1c). A signiﬁcant
increase in the number of colonies in anchorage-dependent
and independent growth was also observed in mut cells, com-
pared to cells expressing either the empty vector or the wt
recombinant protein (one-way ANOVA p< 0.0001, Fig. 1d).
Anchorage-independent growth was monitored as colony for-
mation in soft agar. Mutant MYO1F-expressing cells showed
a signiﬁcant increase in colony formation in soft agar, com-
pared to cells stably transfected with the wt protein or the
empty vector (ordinary one-way ANOVA p5 0.0005; Fig. 1d,
lower panel).
The wound-healing assay, showed that mutant cells had a
signiﬁcantly greater invasive potential after 7 days in culture,
compared to cells stably transfected with the empty vector or
the wt protein, as quantiﬁed with TScratch software14
(ordinary one-way ANOVA p5 0.0024; Fig. 1e). The wound
healing assay was performed in a medium lacking TSH. Since
proliferation of thyroid cells is totally TSH-dependent, we
could discriminate between proliferation and invasiveness.
Therefore, our data do indeed indicate that the mutant cells
have a greater invasive potential.
To relate the observed changes in growth to the activation
of speciﬁc cellular pathways, we investigated different kinases
with key roles in cell proliferation and migration, including
Akt and ERK1/2. We found a speciﬁc increase in the phos-
phorylation of ERK1/2 kinases in cells expressing the mutant
protein, in particular for the p42 isoforms (Figs. 1f and 1g;
p5 0.0042, empty vs. pCMV6 MYO1F G134S). Taken
together, these ﬁndings support a role for the MYO1F muta-
tion in the modulation of tumorigenic potential in vitro (i.e.,
in the modulation of proliferation and invasivity).
Mutant MYO1F p.Gly134Ser stimulates proliferation in
zebrafish embryos
To analyze the pro-proliferative function of MYO1F in vivo,
we evaluated the effects of the human p.Gly134Ser MYO1F
protein in zebraﬁsh (Danio rerio) embryos. The zebraﬁsh
genome encodes a single myo1f orthologue (GenBank ref seq.
NM_001256671.2; NP_001243600.1), with 85% similarity and
76% identity at amino acidic level to human MYO1F. Nota-
bly, the position corresponding to human Glycine 134 is con-
served in the zebraﬁsh Myo1f protein, indicating a putative
functional role of this aminoacidic residue (Supporting Infor-
mation Fig. S1).
To test whether the mutant MYO1F variant can induce cell
proliferation in vivo, one-cell stage embryos were injected with
either wt or p.Gly134Ser MYO1F mutated mRNA. At 48 hpf,
the injected embryos were ﬁxed and stained with antibodies
Figure 2. Proliferation analysis in zebrafish overexpressing either wt or mutant MYO1F p.Gly134Ser: (a,b) Immunostaining of phospho-
histone H3 (pH3) performed in 48 hpf zebrafish larvae. An increase in cell proliferation can be observed in embryos injected with mutant
MYO1F mRNA compared with embryos injected with the wt transcript of MYO1F. (c) Quantification of pH3-positive cells in injected embryos
(48 hpf) was performed with manual counting of mitotic cells (blue nuclei) along the left side of the embryonic trunk, between the yolk
extension and the tip of the tail. For each group, 22 embryos were analyzed (MYO1F_MUT: 25.4562.584; MYO1F_WT: 8.72761.445).
***, p<0.001, Student’s unpaired t test. [Color figure can be viewed at wileyonlinelibrary.com]
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against phospho-histone H3 (pH3), a widely used marker to
reveal cell mitosis in zebraﬁsh.21–23 Embryos injected with the
mutant mRNA showed a signiﬁcant increase in the number of
pH3-positive cells, compared to their siblings injected with the
MYO1F wt allele (Figs. 2a and 2b). In particular, we observed
an increased number of mitotic cells, especially in the caudal
region (p< 0.0001, Fig. 2c) indicating that, when ubiquitously
expressed, the MYO1F mutant protein can induce proliferation
also in zebraﬁsh embryos.
Iodide influx is not altered by the mutation MYO1F
p.Gly134Ser
FRTL-5 cells are highly differentiated thyroid cells and a suitable
model to measure iodide transport in vitro. We measured iodide
uptake by live cell imaging after transient transfection with a
vector encoding YFP-H148Q/I152L, a modiﬁed YFP whose
ﬂuorescence is quenched by I– in a concentration-dependent
manner.15,16 We did not detect any differences in I– uptake
between the different cell lines (one-way ANOVA p5 0.4816;
Supporting Information Figs. S2a and S2b).
Mutation MYO1F p.Gly134Ser alters the mitochondrial
network
Since the oncocytic phenotype is characterized by mitochondrial
hyperplasia in the tumors of affected individuals of the TCO
family,12 we analyzed the mitochondrial network of stably trans-
fected FRTL-5 cells by live-cell microscopy using the Mito-
Tracker Green probe. Mitochondria in the mutant cell lines
appeared more fragmented compared to mitochondria in wt
and empty cell lines (Fig. 3a), as shown by the signiﬁcant
increase in circularity value of mutant cells mitochondria when
compared to wt and empty cell mitochondria (Fig. 3b).
The total mitochondrial mass was signiﬁcantly greater in
mutant cell lines, as determined by MitoTracker ﬂuorescence
quantiﬁcation, normalized for cell viability using a resazurin-
based assay (ordinary one-way ANOVA p< 0.0001; Fig. 3c).
The increase in mitochondrial mass in the mutant cells was
conﬁrmed via Western blotting for voltage-dependent anion-
selective channel (VDAC) (ordinary one-way ANOVA
p5 0.0136, Fig. 3d).
Since an impaired mitochondrial network may alter mito-
chondrial function, we evaluated the levels of proteins and
their phosphorylated forms (phospho-DRP1), involved in
mitochondrial ﬁssion/fusion, that is, DRP1 and MFN1, but
we did not detect any signiﬁcant difference between the vari-
ous cell lines (Figs. 3e and 3f; Supporting Information Figs.
S3a and S3b, respectively).
We measured the mitochondrial membrane potential and
oxidative phosphorylation (OXPHOS) activity of the different
cell lines. The mitochondrial membrane potential was mea-
sured with the probe JC-1,24,25 and normalized for cell viabil-
ity using a resazurin-based assay. No differences were found
between empty vector-expressing cells, wt and mutant cells
(one-way ANOVA p5 0.0720; Supporting Information Fig.
S3c). The addition of oligomycin A did not alter the
ﬂuorescence ratio of JC-1, indicating that ATP hydrolysis by
ATPase was not involved in maintaining the mitochondrial
potential (Supporting Information Fig. S3c).
We measured the ATP/ADP ratio in the different cell
lines, showing that the cells expressing mutant MYO1F
exhibit a signiﬁcant lower ratio in comparison to wt cells,
due to the concomitant decrease in ATP and increase in
ADP levels (p5 0.0289, one-way ANOVA, Fig. 3g). However,
there were no differences in respiratory activity between the
different cell lines under basal conditions (one-way ANOVA
p5 0.5014, Supporting Information Fig. S3d) in the ratio of
FCCP/oligomycin-treated cells (one-way ANOVA p5 0.3900;
Supporting Information Fig. S3e. Extracellular lactate mea-
surement also showed no changes between the different cell
lines (ordinary one-way ANOVA p5 0.4069; Supporting
Information Fig. S3f).
ROS are elevated in FRTL-5 cells expressing MYO1F
p.Gly134Ser
Since differentiated thyroid cells produce a great amount of
hydrogen peroxide (H2O2) necessary for thyroid hormone
synthesis,26 we investigated whether reactive oxygen species
(ROS) production in transfected FRTL-5 cell lines was
deranged by the MYO1F mutation.
Intracellular ROS levels, measured with the ﬂuorescent
probe DCF-DA, were signiﬁcantly increased in the mutant
cells (one-way ANOVA p5 0.0015, Fig. 4a). To understand
whether this phenomenon was due to alterations/decreases of
intracellular ROS detoxifying enzymes, we performed West-
ern blotting analysis of catalase, mitochondrial manganese
superoxide dismutase (SOD2) and peredoxin-3 (Prx3), using
GAPDH as endogenous reference. The steady state levels of
the analyzed proteins were not signiﬁcantly different between
all cell lines (Fig. 4b; Supporting Information Figs. S4a–S4c;
one-way ANOVA p5 0.1328 for catalase, p5 0.8592 for
SOD2, p5 0.6837 for Prx3).
Interestingly, treatment for 24 hrs with the antioxidant com-
pound NAC partially recovered the defects in the mitochondrial
network in cells expressing mutant MYO1F, conﬁrming the role
of ROS in mitochondrial fragmentation (p< 0.0001; Fig. 4c). In
concordance, we observed a decrease in cell invasion between
the FRTL-5 cell lines treated with NAC, compared to the
untreated ones, as measured by the wound healing assay (Stu-
dent’s t test, untreated vs. treated p5 0.0236 pCMV6 empty,
p5 0.0338 pCMV6-MYO1F wt, p5 0.0488 pCMV6-MYO1F-
G134S; Fig. 4d). This effect was observed in all cell lines, not
only for the mutant MYO1F cells.
To measure extracellular ROS, we used the ﬂuorescent
probe Amplex Red, which is unable to cross the plasma
membrane. We observed a signiﬁcantly higher amount of
extracellular ROS in mutant cell lines, compared to the
empty vector-transfected cells and the wt ones. Moreover, we
detected, a signiﬁcant decrease in extracellular ROS in the
cells expressing MYO1F wt, when compared to the empty
vector (one-way ANOVA p5 0.0004; pCMV6-empty vs.
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Figure 3. Mitochondrial defects in FRTL-5- MYO1F p.Gly134Ser cells. (a) Representative fluorescence images of pCMV6-empty, pCMV6-MYOF
wt, and pCMV6-MYOF G134S stained with Mitotracker Green to evaluate mitochondrial network. The cells expressing the mutant protein
show more circular (b) and more abundant (c) mitochondria and more fragmented mitochondrial network in comparison with wt and cells
bearing empty vector. MitoTracker signal quantification was normalized on viable cell number assessed by resazurin-based assay. (d) Rep-
resentative image of Western blotting analysis for VDAC in pCMV6-empty, pCMV6-MYOF wt, and pCMV6-MYOF G134S cells and relative
quantification, compared to reference protein (vinculin). Scale bars indicate standard errors. Stars indicate significant p values. (e–f) Repre-
sentative images of Western blotting analysis for DRP1-phospho-DRP1 (e) and MFN1 (f) in pCMV6-empty, pCMV6-MYOF wt, and pCMV6-
MYOF G134S cells. (g) ATP/ADP ratio in cellular extracts from pCMV6-empty, pCMV6-MYOF wt, and pCMV6-MYOF G134S cells, showing a
decreased ATP/ADP ratio in the mutant FTRL5 cells. Scale bars indicate standard errors. Stars indicate significant p values. [Color figure can
be viewed at wileyonlinelibrary.com]
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Figure 4. ROS production. (a) Intracellular ROS production measured by DCFDA fluorescent probe. Data show a significant ROS production
increase in the FRTL-5 cells expressing MYO1F p.Gly134Ser in comparison to wt and cells bearing the empty pCMV6 vector. Data are expressed
as arbitrary fluorescence units6SD, normalized on viable cell number. (b) Representative Western blot analysis showing the expression of
detoxifying enzymes (catalase, SOD2, and Prx3) in the three cell lines. GAPDH was used as endogenous loading control. (c) Representative
fluorescence images of pCMV6-empty, pCMV6-MYOF wt, and pCMV6-MYOF G134-S cells stained for 24 hrs with 1 mM N-acetyl-L-cysteine (NAC)
or vehicle. Live cells were stained with 40 nM Mitotracker Green to evaluate mitochondrial network. Circularity value analysis was performed
using ImageJ software standard tool. Data indicate a significant recovery for the NAC-treated mutant cells versus the untreated mutant ones.
(d) Wound healing assay in presence of NAC and relative quantification, showing a significant decrease in invasive potential in the cell lines.
(e) Extracellular ROS production measured by Amplex red fluorescent probe. Data show that FRTL-5 cells expressing MYO1F p.Gly134Ser pre-
sented the highest levels of extracellular ROS, whereas the cells expressing the wt protein presented a reduced amount of extracellular ROS.
Data are expressed as arbitrary fluorescence units6SD normalized on viable cell number. Cell viability was assessed by resazurin-based
method. (f) Representative image of Western blotting analysis for NOX1 in pCMV6-empty, pCMV6-MYOF wt, and pCMV6-MYOF G134S cells.
[Color figure can be viewed at wileyonlinelibrary.com]
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pCMV6-MYO1F wt p< 0.05; pCMV6-MYO1F wt vs.
pCMV6-MYO1F G134S p< 0.001; Fig. 4e). We evaluated
NOX1 protein levels, but we did not detect any signiﬁcant
variation between the different cell lines (Fig. 4f; Supporting
Information Fig. S4d; one-way ANOVA p5 0.5900).
Mutation screening of human MYO1F in FNMTC patients
To identify additional patients carrying predisposing germline
mutations in MYO1F, we performed a mutation screening via
Sanger sequencing of genomic DNA from peripheral blood of
192 independent FNMTC cases. These patients represented a
heterogeneous group of cases affected by PTC/FTC, and the
presence of oncocytic features was not always investigated.
These data were available only for a small subgroup of patients
(Supporting Information Table S1). We identiﬁed several rare/
novel coding variants in MYO1F (Table 1), including a rare
silent change in exon 7, present in both the affected individuals
of the corresponding family, from whom DNA was available
(Supporting Information Fig. S5a). This change potentially
removed an exonic sequence enhancer (ESE) in exon 7, as pre-
dicted by the ESE Finder v3.0 program (Supporting Information
Fig. S5b). The change, corresponding to the genomic coordi-
nates chr19:g.8616995C>T (rs184748543), was present with a
minor allele frequency (MAF) of 0.003168 in the general popu-
lation and a MAF of 0.004224 in individuals of European
ancestry-only (gnomAD; Table 1). The variant frequency was
not signiﬁcantly different between the NMTC cases and general
population controls; moreover, one individual in the gnomAD
database was homozygous for the variant allele, suggesting that
it might have no severe functional consequences.
Nevertheless, to study whether it could hamper the inclusion
of exon 7 in the ﬁnal MYO1F transcript, since no fresh RNA was
available from the affected patients carrying the rs184748543 vari-
ant allele, we generated a minigene plasmid carrying either the wt
or mutant sequence, and transfected simian COS7 cells to study
transcription (Figs. 5a and 5b). RT-PCR with minigene-speciﬁc
synthetic primers and direct sequencing revealed that the wt exon
was correctly spliced, whereas the mutant transcript lacked exon
7 (Fig. 5c). This altered transcript is predicted to produce a
shorter MYO1F protein, with an in-frame deletion of 43 amino
acids (G169-Q212) in the motor domain of MYO1F, that may
alter the structure of the ATP-binding domain in the molecular
motor of MYO1F (residues 110–117 and 162–166; Fig. 5d).
Discussion
The etiology of differentiated thyroid cancer is still poorly
understood, but this type of cancer is inﬂuenced by both
genetic and environmental factors. Large genome-wide case–
control association studies have identiﬁed genetic variants
conferring NMTC susceptibility in the general popula-
tion.27–29 A number of common single nucleotide polymor-
phisms (SNPs) have been reported to be associated with
NMTC risk, but few studies have been conducted in high-
risk NMTC families to examine the transmission of the risk
allele to the affected members.30
In our study, we report the identiﬁcation of MYO1F as
the gene mutated at the TCO locus. We provide functional
evidence that the MYO1F p.Gly134Ser mutation leads to an
increased oncogenic potential in vitro, in terms of cell growth
and invasion. FRTL-5 cells, a cell model resembling a functional
thyrocyte,13 stably transfected with the plasmid encoding mutant
MYO1F p.Gly134Ser showed increased proliferation, generated
signiﬁcantly more colonies in soft agar and showed a signiﬁ-
cantly greater invasive potential compared to cells stably trans-
fected with the empty vector or with wt MYO1F.
These in vitro data were supported by in vivo ﬁndings in
zebraﬁsh, showing that the mutant MYO1F p.Gly134Ser,
when overexpressed, can induce proliferation in whole verte-
brate embryos, supporting the idea that the novel missense
change identiﬁed in exon 5 of MYO1F is the causative muta-
tion at the TCO locus.
The TCO locus in the original pedigree was associated
with an oncocytic phenotype, that is, enriched in mitochon-
dria.12 Previous work by our group uncovered a tight correla-
tion between the co-occurrence of mitochondrial DNA
(mtDNA) alterations in oncocytic thyroid cancer, and a
marked dysfunction of OXPHOS complexes, in particular
complex I.31–33 Since thyroid follicular cells generate H2O2 by
membrane-bound dual oxidases for the synthesis of thyroid
hormones, these cells are at increased risk of oxidative stress
Table 1. Rare coding variants identified in MYO1F-targeted mutation screening
Chr19 genomic position (hg19)
Amino acid change
(NP_036467)
MAF in famNMTC
(N5192)
MAF in gnomAD
(European only)
g.8616995 C>T rs184748543 p.Lys1861 0.0026 0.004224
g.8615552C>T rs201962739 p.Pro266 0.0026 0.001478
g.8615513C>G p.Gly3682 0.0026 0
g.8610599G>T p.Ile430 0.0026 0
g.8587411C>T rs201982814 p.Val1024Met3 0.0026 0.00074554
1SNV not changing the corresponding amino acid, but with an altered ESE profile compared to wt cDNA, and removing SR-binding domains. The
SNV co-segregated with the NMTC phenotype in the available members of the corresponding family.
2SNV not segregating with the NMTC phenotype in the corresponding families.
3Missense variant predicted to be “benign” (PolyPhen-2) and “tolerated” (SIFT).
4One homozygous individual present in European population.
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Figure 5. MYO1F rs184748543. (a) Map of the minigene plasmid, showing the genomic insert of the wt and mutant alleles (red arrows).
(Blue arrows5position of the primers used for the specific RT-PCR). (b) RT-PCR of COS7-transfected with the MYO1F allele-specific mini-
genes. Upper panel: predicted final transcripts generated by the correct splicing of mini-gene-specific exons (blue) and MYO1F-specific
exons (grey). Lower panel: 2% agarose gel image (left) of the RT-PCR products, showing the different sizes of the transcripts and corre-
sponding electropherograms (right): the wt MYO1F allele promoted the inclusion of the exon 7 in the final transcript, whereas the mutant
allele induced an exon skipping in the final transcript, as predicted by the removal of the ESE in the exon 7. (d) Structure prediction of the
MYO1F molecular motor region, with the ATP-binding region highlighted in green. Pink indicates the residues corresponding to exon 7 and
red is the ion of magnesium. [Color figure can be viewed at wileyonlinelibrary.com]
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and ROS-mediated DNA damage. Indeed, an imbalance
between pro- and anti-oxidative factors has been suggested as
an important mechanism in thyroid tumorigenesis.34,35 Oxi-
dative stress generated by mitochondrial dysfunction can also
promote migration and stimulate MAPK-mediated cell death.
We therefore sought to evaluate: (i) the functionality of the
mitochondrial respiratory chain as a whole; (ii) the response
to oxidative stress of FRTL-5 cells stably expressing the wt or
mutant recombinant MYO1F protein, compared to cells
expressing the empty-vector. We found that the mitochon-
drial membrane potential and OXPHOS activities were simi-
lar in all cell lines, suggesting that mitochondria were still
functional. However, analysis of the mitochondrial network
by live-cell visualization revealed that in the mutant cell lines,
mitochondria appeared as separated rod-shaped organelles.
The mitochondrial features of mutant MYO1F cells were
therefore reminiscent of the oncocytic features described pre-
viously in the tumor tissues of the patients carrying the
p.Gly134Ser change.12
In our experimental setting, we found that cells with the
MYO1F p.Gly134Ser mutation, in addition to having an
altered mitochondrial network and an increased mitochon-
drial mass, produced signiﬁcantly more intracellular and
extracellular ROS.
It has been reported that the establishment and mainte-
nance of a transformed state is related to the presence of
extracellular ROS, in particular, superoxide anion generated
by a speciﬁc membrane-associated NADPH-oxidase, NOX1.35
In fact, oncogenic activation of proliferative/mitogenic path-
ways has been associated with increased ROS production due
to activation of the membrane-bound NADPH oxidases.36
We did not detect differences among NOX1 protein levels,
but this ﬁnding did not exclude an increased activation of
this enzyme in the cells carrying the mutant MYO1F protein.
Extensive analysis of tumor cell lines derived from different
tissues, including thyroid carcinomas, has shown that they
were all characterized by extracellular ROS generation, not
found in cells derived from normal tissues.34 This is paral-
leled by our ﬁndings, since extracellular ROS production was
increased only in FRTL-5 cells expressing the mutant
MYO1F p.Gly134Ser protein, suggesting that the mutation is
sufﬁcient to generate a transformed phenotype.
Interestingly, when the cells with the MYO1F p.Gly134Ser
mutation were treated with an antioxidant (NAC), we
observed a partial but signiﬁcant rescue of the mitochondrial
fragmentation, conﬁrming the role of ROS in this phenome-
non.37 In agreement with this result, treatment with NAC also
decreased the invasiveness of all cell lines including mutant
MYO1F cells, as indicated by the wound-healing assay. These
pilot data on phenotype rescue suggest that the treatment with
antioxidants may be effective for this type of tumors.
Since the “mitochondria-rich” phenotype may be under-
reported by histologic analysis,32 we screened additional
FNMTC patients to identify other MYO1F germline variants
that could predispose to thyroid tumor development.
However, the available samples represented a heterogeneous
group of familial cases affected by NMTC, and the high
genetic heterogeneity of thyroid cancer might have hampered
the discovery of a number of additional predisposing variants
in MYO1F. We identiﬁed a rare variant in two affected sibs
in exon 7, which promoted the skipping of the exon from
mature mRNA in vitro. No data regarding the presence of an
oncocytic phenotype were available for the two affected sibs.
In addition, the unavailability of fresh RNA from tissues of
these patients prevented us from conﬁrming that this exon
skipping event actually occurs in vivo. Moreover, the allele
frequency of the exon 7 variant allele in our FNMTC cases
was not signiﬁcantly different from the one present in the
control individuals in public databases; therefore, its contri-
bution to NMTC predisposition remains elusive. Our results
regarding MYO1F mutation screening in FNMTC cases stress
once again the high genetic heterogeneity underlying familial
thyroid cancer. Nevertheless, our study shows that a defective
MYO1F protein promotes the development of an oncocytic
phenotype, that is, mitochondrial proliferation, indicating
that this cellular characteristic can develop not only from
mitochondrial DNA defects31–33 but also from nuclear defects
in speciﬁc genes, that is, MYO1F. Mitochondrial dysfunction
and stress has been widely related to cancer, in particular, in
thyroid cancer predisposition.31,32 More broadly, an altered
mitochondrial function is a hallmark of many cancers,
although the nature of functional modiﬁcation depends on
the type of cancer.33
It is interesting to note that F-actin is one of the few known
interactors of MYO1F20 and has been recently implicated in
mitochondrial ﬁssion control.38 Blockade of F-actin polymeriza-
tion/depolymerization altered the mitochondrial network.38 Sim-
ilarly to what has been observed in other autosomal dominant
disorders due to mutations in myosin genes, such as MYH9,39,40
we can hypothesize that the modiﬁed conformation of MYO1F
may block actin ﬁlament recycling; therefore, concurrently alter-
ing the mitochondrial network organization.
Recent data have shown the contribution of mitochondrial
dynamics toward tumor initiation and progression, although
the exact mechanism is not known. Excessive ﬁssion and
reduced fusion is a feature of many tumors.41–43 For example,
in human pancreatic cancer, expression of oncogenic Ras/
activation of MAPK pathway induces ERK2-mediated Drp1
phosphorylation leading to increased mitochondrial fragmen-
tation and the inhibition of this phosphorylation in xeno-
grafts is sufﬁcient to block tumor growth.44 Interestingly,
recent data indicated that ERK2 also phosphorylated MFN1
to control mitochondrial morphology and apoptosis.45 We
did not ﬁnd difference in Drp1 levels and phosphorylation in
our cell models, and it will be of interest to evaluate also this
pathway in the framework of the observed altered mitochon-
drial network present in the mutant MYO1F cells.
It is becoming increasingly clear that mitochondrial ﬁssion
and fusion play a critical role in quality control and mito-
chondrial damage/repair in cancer. Therefore, our data
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showing a fragmented mitochondrial network due to MYO1F
p.Gly134Ser mutation highlight a potential novel pathway
that may be deranged in thyroid cancer, that is, an altered
myosin/F-actin regulated interaction.20
To date, no other mutations have been reported in myosin-
encoding genes in thyroid cancer; however, it is interesting that
MYH9, a non-muscle myosin involved in sensorineural deafness
and thrombocytopenia,39,40 has recently been found to regulate
the ncRNA genes PTCSC2 and FOXE1 at the 9q22 thyroid can-
cer susceptibility locus.46 In the TCGA database, somatic muta-
tions in MYO1F are reported in 352 cases from various cancer
types (Supporting Information Fig. S6a). The mutation identi-
ﬁed at the TCO locus in MYO1F was not reported. In the COS-
MIC database several mutations are present in MYO1F in
different types of cancer (Supporting Information Fig. S6b),
but only a somatic variant is reported in thyroid carcinoma
(COSM4132813). However, MYO1F overexpression was re-
ported in 24 of 513 (4.68%) cases (Supporting Information
Fig. S6c). These and our data suggest that MYO1F dysregulation
may predispose to cancer in a subgroup of cases. Indeed, the
oncocytic phenotype, observed in the family with the MYO1F
p.Gly134Ser mutation, represents a speciﬁc, although rare, group
of thyroid neoplasms, in which MYO1F mutation screening
may be more relevant than in other FNMTC cases. The identiﬁ-
cation of the molecular cause(s) of speciﬁc thyroid cancer sub-
types will help tailor patients’ treatment for a more personalized
therapy.
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